Our Company
Vascular Closure Systems, Inc. is a privately held medical device company, focused on the development and commercialization of the next generation vascular access closure technology for the Interventional Cardiology market. The company is comprised of several seasoned medical device professionals and world class physicians, with a proven record of innovation, clinical acumen, access to the industry and successful commercialization of multiple medical device technologies. Vascular Closure Systems, Inc. is ISO 13485 compliant.
The Market
There are more than 12 million endovascular procedures performed annually which require percutaneous access, primarily through the femoral artery. These vascular access punctures require rapid closure and careful management immediately following the procedure. The overall market for vascular closure is estimated to be over USD $2 billion. Due to an aging population and rapid increase in cardiovascular diseases, the catheter-based endovascular procedures market continues to grow. The growth rate of the vascular closure market is estimated at 10% to 15% annually. The current market is estimated to be only 30% to 35% penetrated.
Our Technology
Our technology is based on more than ten issued and pending patents (with priority dates going back to 2000), and has been engineered to be easier to learn, easier to use and more cost effective than current vascular closure systems. Our Intellectual Property (IP) covers three different types of sealing methods - a swellable, bioabsorbable tubular plug, a self-closing nitinol clip and RF thermal closure. All three vessel sealing methods remain completely extravascular during and after deployment. Each of the sealing method systems include versions designed for either temporary use (removable), - leaving nothing behind, or as a permanent implant. Our vascular closure systems do not require a second device (deployment or infusion) to be inserted or reinserted into the puncture site. Our technology is scalable for use with medical devices, from less than 6 Fr. to larger than 20 Fr. Additionally, our vascular closure systems may be packaged already loaded onto a vascular introducer, catheter, guide catheter, guide wire, etc. Our vascular access closure system would be particularly beneficial and enabling for larger sized catheter-based percutaneous procedures, including heart valve reinforcement / replacement.
The Company has recently closed a second round of funding.
Company representatives will be attending the following upcoming medical conferences:
September - National Congress of the Italian Society of Invasive Cardiology, Bologna
October - Transcatheter Cardiovascular Therapeutics (TCT), Washington, D.C.
November - American Heart Association (AHA), New Orleans, LA
The company expects to file at least one regulatory submission in the near future and is currently establishing the US and International distribution network.
Please note that the company's devices have not yet been approved by the US FDA and are not for sale or use in the US.
